We examined 15 urinary estrogens/estrogen metabolites and breast cancer risk among premenopausal women in a case-control study nested within the Nurses' Health Study II (NHSII). From1996 to 1999, urine was collected from 18,521 women during the mid-luteal menstrual phase. Breast cancer cases (...
Professor Ian Smith, Head of the Breast Unit at The Royal Marsden, said: "The Royal Marsden is particularly pleased at this major advance for women with breast cancer everywhere, as we were the main team involved in the development of letrozole, one of the most effective of the aromatase in...
In a genome-wide analysis, progesterone receptor was among the least variable genes in ER- breast cancer. The ER-/PR+ subtype was rare (approximately 1 to 4%) and showed no significant reproducibility (Kappa = 0.02 and 0.06, in the GEM and NHS datasets, respectively). The vast majority ...
In a human-in-mouse model of ER+/HER2+ breast cancer, adjuvant paclitaxel plus trastuzumab ± pertuzumab for 4 weeks, followed by “extended adjuvant therapy” with fulvestrant plus neratinib for an additional 4 weeks, was associated with maintenance of a complete response (CR), whereas ...
Approximately 70% of breast cancers are estrogen-receptor positive. Tamoxifen and aromatase inhibitors have been the mainstay of endocrine therapy and have improved breast cancer survival. However, a large number of patients experience disease recurrence either during or following completion of endocrine ...
www.nature.com/npjbcancer ARTICLE OPEN Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer Sunil Pancholi 1, Nikiana Simigdala1, Ricardo Ribas1, Eugene Schuster1, Mariana Ferreira Leal1, Joanna ...
The role of estrogen receptors (ERs) in hormone-dependent breast cancer is the focus of many clinical studies because the receptor content gives the most accurate index of the cancer [135], [136], [137]. ERs are considered to be target proteins of a number of compounds known as endocrine...
Methods: We computed percent agreement and Kappa statistics for ER/PR status as reported in pathology reports from Nurse's Health Study (NHS) participants with breast cancer from 1976 to 2000, and as scored by immunohistochemistry (IHC) on tissue microarrays at a central laboratory (n = 2011)...
Institute of Systems, Molecular and Integrative Biology, University of Liverpool & Clatterbridge Centre NHS Foundation Trust, Liverpool, UK Carlo Palmieri Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK Jason S. Carroll ...
The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 115, 3189–3195, doi: 10.1002/cncr.24374 (2009). 27. Kornhuber, J. et al. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical...